ProQR Therapeutics N.V. (PRQR) Earns Daily Media Impact Score of 0.07
News articles about ProQR Therapeutics N.V. (NASDAQ:PRQR) have trended somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ProQR Therapeutics N.V. earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.721728912912 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics (finance.yahoo.com)
- Zacks Investment Research Lowers ProQR Therapeutics N.V. (PRQR) to Hold (americanbankingnews.com)
- ProQR Therapeutics N.V. (PRQR) Given Consensus Rating of “Hold” by Analysts (americanbankingnews.com)
- ProQR’s QRX-421 for Usher Syndrome receives ODD from FDA and EMA (seekingalpha.com)
- ProQR’s QRX-421 Gets Orphan Drug Designation from FDA and EMA (zacks.com)
ProQR Therapeutics N.V. (NASDAQ:PRQR) traded up 9.26% during mid-day trading on Wednesday, reaching $5.90. 66,909 shares of the company were exchanged. ProQR Therapeutics N.V. has a one year low of $3.65 and a one year high of $8.70. The stock’s market capitalization is $142.22 million. The stock has a 50 day moving average of $5.03 and a 200-day moving average of $4.93.
Several analysts have recently issued reports on the stock. Zacks Investment Research raised shares of ProQR Therapeutics N.V. from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a research report on Wednesday. ValuEngine raised shares of ProQR Therapeutics N.V. from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of ProQR Therapeutics N.V. in a research report on Tuesday, June 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $14.30.
WARNING: “ProQR Therapeutics N.V. (PRQR) Earns Daily Media Impact Score of 0.07” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/13/proqr-therapeutics-n-v-prqr-earns-daily-media-impact-score-of-0-07.html.
ProQR Therapeutics N.V. Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Stock Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related stocks with our FREE daily email newsletter.